Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 4Completed 4Active not recruiting 3Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 54Other hematologic neoplasm 29Breast 27Gastrointestinal 23Thoracic 22Lymphoid 21Genitourinary 14Gynecologic 12Myeloid 11CNS 5Plasma cell 4Head & Neck 4NET 3Endocrine 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Classical hematology 2Other 1

Conditions

Melanoma 2Ovarian Neoplasms 1Lymphoma, T-Cell 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Injections × Dermatologic × Clear all
NCT04752826 2026-02-18

MK-3475-D20

BioInvent International AB

Phase 1/2 Recruiting
176 enrolled
DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06209580 2025-09-05

AMT-253 in Patients With Advanced Solid Tumours

Multitude Therapeutics Inc.

Phase 1/2 Recruiting
96 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡